DLI 150326_Catenion_8264

“We help our clients to achieve best practise in managing R&D performance”

Webpage Slider Anela Vukoja

„How can patients and the legislature steer the biopharmaceutical industry towards sustainable innovation?“

Webpage Slider Pascal Joly

“At Catenion, I can put into practical use my scientific background in cell therapy and regenerative medicine and help bringing to the market innovative therapies.“

Pascal Joly Analyst
Webpage Slider Sarah Oelsner

“From bench to bedside and beyond: Translating inspiring science into innovative business strategies is a fascinating journey”

Webpage Slider John Herrmann
John Herrmann, Ph.D. Expert Partner
Sophie von Dyrander

“My decision to join Catenion? Here I found what I was looking for – high level strategy work, international clients and the team spirit of a smaller firm.”

Webpage Slider Arno Heuermann

“Translating new technologies into viable business ideas”

Arno Heuermann COO, Partner, Managing Director
COG 150326_Catenion_0233

“I help R&D teams deliver on the promise of gene therapy”

Christian Elze

“China’s policy makers are making a concerted long-term effort to build a competitive biomedical innovation system – but R&D-based value creation
is only just beginning.”

Christian Elze Senior Partner
Markus Thunecke

“Is biopharma ready to embrace the new biology?”

Dr. Markus Thunecke Senior Partner
Matthias Krings

“Change-Management is a team effort – let’s get started”

Dr. Matthias Krings Senior Partner
Graham Scholefield

“Sitting at the boundary between science and business is an incredibly rewarding experience”


Organising for creativity and innovation – lessons from the biopharmaceutical industry

Financier worldwide, December 2016 The biopharma industry is arguably the most knowledge intense industry of all. Human creativity ….
Download this article

Biopharma’s Brave New Biology

The Medicine Maker – January 2016 - We live in exciting times for the biopharma industry. The 100-year-old promise of cancer immunotherapy turning cancer into a chronic (if not curable) disease seems within reach in selected indications. …
Download this article

Meet Us

November 2 - 3, 2016

NY/NJ CEO, New York

November 7–9, 2016

Bio-Europe, Cologne, Germany

Nov 9, 2016

Kyoto University Graduate School of Medicine

January 28, 2017

The New York Academy of Science

Feb 1st, 2017

Tokyo University – Cultural Challenges in Translational Research

April 11, 2017

Boston Biotech Conference, Harvard Medical School, Boston

2. - 3. March 2017

Pharmaceutical PPM Toolbox, London